INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of September 30, 2014 and December 31, 2013:

	September 30, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(1,997	)	$	29,954		15
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		387,806		(13,616	)		374,190		18.25
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents		340,059		—			340,059		n/a
(pending)
Multiple trademarks for
vitamins/supplements		97,538		—			97,538		n/a
Total	$	949,097	$	(107,356	)	$	841,741

	December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
Development costs of
corporate website		91,743		(89,661	)		2,082		0.3
Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents (pending)		572,726		—			572,726		n/a
Multiple trademarks for
vitamins/supplements		59,328		—			59,328		n/a
Total	$	755,748	$	(90,160	)	$	665,588

Schedule of estimated amortization expense

Amortization expense was $5,625 and $3,255 for the three months ended September 30, 2014 and 2013, respectively and $17,196 and $9,764 for the nine months ended September 30, 2014 and 2013, respectively. Estimated amortization expense for the next five years is as follows:

Year Ending December 31,	Estimated Amortization
2014 (3 months)	$5,625
2015	$22,500
2016	$22,500
2017	$22,500
2018	$22,500